EICHORPublic-registry site landscape for NCT02786732, “Study to Evaluate Broadlumab vs Placebo and Ustekinumab”, a Psoriasis study sponsored by MedDerm Associates. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02786732 (registry record) |
| Study title | Study to Evaluate Broadlumab vs Placebo and Ustekinumab |
| Official title | Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis |
| Sponsor | MedDerm Associates |
| Condition(s) | Psoriasis |
| Phase | PHASE3 |
| Listed sites | 1 |
| Intervention(s) | 210mg Brodalumab, 140mg Brodalumab, Ustekinumab, Placebo |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02786732.
Eichor generates a preliminary site-risk snapshot for NCT02786732 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Psoriasis trials
← Eichor home · All tracked trials · Psoriasis studies · Weekly briefs
